Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia

Next Previous
Trial Profile

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avexitide (Primary)
  • Indications Hypoglycaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms LUCIDITY
  • Sponsors Amylyx Pharmaceuticals

Most Recent Events

  • 30 Apr 2025 According to an Amylyx Pharmaceuticals media release, first participant has been dosed in this trial, The Company continues to expect cash runway through the end of 2026, which will support the completion of recruitment for the pivotal Phase 3 LUCIDITY clinical trial of avexitide in PBH expected in 2025.
  • 04 Mar 2025 According to an Amylyx Pharmaceuticals, data readout from this trial anticipated in the first half of 2026.
  • 07 Feb 2025 Planned initiation date (estimated date of first participant enrollment) changed from 1 Jan 2025 to 1 Feb 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top